This document provides an update on clinical practice guidelines for diabetes mellitus and its impact on the heart. It discusses recent studies that have shown the effectiveness of certain medications in reducing the risk of heart failure and cardiovascular events in patients with diabetes. The document emphasizes the increased cardiovascular risk associated with diabetes and the importance of targeted risk stratification and treatment. It provides recommendations for reducing cardiovascular risk through lifestyle changes, medication, and blood pressure management. The document also discusses the relationship between diabetes and coronary heart disease, as well as the increased risk of heart failure in patients with diabetes. It provides information on the treatment of heart failure in patients with diabetes, stating that the treatment does not differ between patients with and without diabetes and recommends a specific quadruple therapy. The document also mentions the use of SGLT2 inhibitors in reducing heart failure in patients with and without diabetes, as well as a new mineralocorticoid receptor antagonist for patients with diabetes, chronic kidney disease, and albuminuria. Lastly, it provides information on the management of atrial fibrillation in patients with diabetes. [Extracted from the article]